ORPHA:832
Succinyl-CoA:3-oxoacid CoA transferase deficiency
Also known as: OXCT1 deficiency · SCOT deficiency · Succinyl-CoA acetoacetate transferase deficiency · Succinyl-CoA:3-ketoacid CoA transferase deficiency
Publications
1,393
Trials
0
Interventional, condition-specific
Researchers
1,191
Distinct authors in sample
Gene link
OXCT1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic disorder in ketone body utilization characterized by severe, potentially fatal intermittent episodes of ketoacidosis.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009492
- MeSH:C537527
- OMIM:245050
- UMLS:C0342792
Additional Mondo synonyms (4)
Succinyl CoA:3-oxoacid CoA transferase deficiency · succinyl-CoA acetoacetate transferase deficiency · succinyl-CoA:3-ketoacid CoA transferase deficiency · succinyl-CoA:3-oxoacid CoA transferase deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — OXCT1
- LiteraturePresent
1,393 matched papers (1,088 in last 10 years) Source
- Phenotype characterisedPresent
20 HPO annotations (e.g. Hyperketonemia; Failure to thrive in infancy; Ketoacidosis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (OXCT1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
20
Associated phenotypes · MONDO:0009492
- Hyperketonemia
- Failure to thrive in infancy
- Ketoacidosis
- Vomiting
- Lethargy
Showing 5 of 20 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,393
1,393 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,393 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,088 in the last 10 years · low confidence
Phrase hits: 204 · MeSH hits: 0
Who's working on it?
1,191
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Fukao T22 papers · 2017
Department of Pediatrics, Gifu University School of Medicine, Gifu, Gifu, 500-8076, Japan. toshi-gif@umin.ac.jp
Papers in Europe PMC - 02Kondo N15 papers · 2013Papers in Europe PMC
- 03Crawford PA7 papers · 2023
Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, FL 32827, USA. Electronic address: pcrawford@sbpdiscovery.org.
Papers in Europe PMC - 04Chen Y6 papers · 2025
National Heart Lung and Blood Institute, NIH, 31 Center Drive, Building 31, Bethesda, MD 20892, USA.
Papers in Europe PMC - 05Sass JO6 papers · 2021
Bioanalytics & Biochemistry, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, von-Liebig-Str. 20, 53359, Rheinbach, Germany. joern.oliver.sass@h-brs.de.
Papers in Europe PMC - 06Mitchell GA5 papers · 2001Papers in Europe PMC
- 07Shintaku H5 papers · 2004Papers in Europe PMC
- 08Song XQ5 papers · 2000
Department of Pediatrics, Gifu University School of Medicine, Japan.
Papers in Europe PMC - 09Hirayama K4 papers · 1998Papers in Europe PMC
- 10Kassovska-Bratinova S4 papers · 2000
Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal, Québec, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 13 · after dedupe 13 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 13 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (13)
- isrctn·ISRCTN15518794·No longer recruiting·Assessment of itch symptoms in primary sclerosing cholangitis and other chronic liver diseases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12180483·No longer recruiting·Probiotics in Paget's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14762022·No longer recruiting·A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedema
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15449782·No longer recruiting·The effect on bacteria of breathing in (through an inhaler) a drug which reduces swelling (a steroid) in severe COPD (chronic obstructive pulmonary disease) patients with associated widening of the air tubes (bronchiectasis)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17672960·No longer recruiting·A study to assess the safety of selnoflast in participants with chronic obstructive pulmonary disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48609976·No longer recruiting·Comparing gonadotrophin-releasing hormone analogues with repeat laparoscopic surgery for the treatment of recurrent pain following surgery for endometriosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17598292·No longer recruiting·Testing if the SonoTran Platform can enhance drug delivery in metastatic colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16993428·Recruiting·GenOMICC study - Looking at DNA of patients with severe illness and injury to find the genes that cause some people to become very unwell and be admitted to intensive care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10249134·No longer recruiting·What is the clinical effectiveness and cost-effectiveness of nebulised 7% sodium chloride in patients with chronic obstructive pulmonary disease?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16004234·Stopped·A multi-arm non-comparative platform trial of new second-line treatments for metastatic pancreatic cancer patients based on a patient's individual biomarkers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10176118·No longer recruiting·A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valproate in paediatric and adult patients with Wolfram Syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34129115·Stopped·PRIMUS002: A study looking at two neo-adjuvant chemotherapy treatments for pancreatic cancer in patients whose cancer is able to be operated on
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59757862·No longer recruiting·SCOT - Short Course Oncology Therapy: a study of adjuvant chemotherapy in colorectal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Succinyl-CoA:3-oxoacid CoA transferase deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Succinyl-CoA:3-oxoacid CoA transferase deficiency" OR "OXCT1 deficiency" OR "SCOT deficiency" OR "Succinyl-CoA acetoacetate transferase deficiency" OR "Succinyl-CoA:3-ketoacid CoA transferase deficiency" OR "Succinyl CoA:3-oxoacid CoA transferase deficiency") OR ("OXCT1" OR "OXCT1 syndrome" OR "OXCT1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Succinyl-CoA:3-oxoacid CoA transferase deficiency" OR "OXCT1 deficiency" OR "SCOT deficiency" OR "Succinyl-CoA acetoacetate transferase deficiency" OR "Succinyl-CoA:3-ketoacid CoA transferase deficiency" OR "Succinyl CoA:3-oxoacid CoA transferase deficiency"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1393) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T15:35:28.685Z
